Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The Company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain.

Show more
Type
Public
HQ
Cambridge, US
Founded
2000
Size (employees)
23 (est)
Website
infi.com
Infinity Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Infinity Pharmaceuticals

David Roth

David Roth

Senior Vice President, Clinical Development and Medical Affairs
Joseph McPherson

Joseph McPherson

Vice President, Vendor Management/Sourcing and Facilities Operations
Lawrence Bloch

Lawrence Bloch

Executive Vice President, Chief Financial Officer and Chief Business Officer
Julian Adams

Julian Adams

President, Research and Developmen
Tamyra Toole

Tamyra Toole

Vice President, Regulatory Affairs and Quality Assurance

Infinity Pharmaceuticals Office Locations

Infinity Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
780 Memorial Drive
Show all (1)
Report incorrect company information

Infinity Pharmaceuticals Financials and Metrics

Infinity Pharmaceuticals Financials

Infinity Pharmaceuticals's revenue was reported to be $18.72 m in FY, 2016 which is a 82.8% decrease from the previous period.
USD

Net income (Q1, 2018)

(9.5 m)

EBIT (Q1, 2018)

(9.5 m)

Market capitalization (14-Jun-2018)

96.4 m

Closing share price (14-Jun-2018)

1.7

Cash (31-Mar-2018)

30.6 m
Infinity Pharmaceuticals's current market capitalization is $96.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

165 m109.1 m18.7 m

Revenue growth, %

(34%)(83%)

General and administrative expense

42.2 m21.6 m

R&D expense

119.6 m20.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

7.3 m6.8 m7.1 m8 m8.6 m9.4 m9.8 m10.8 m15.7 m7.1 m6.4 m6.2 m3.6 m

R&D expense

26.9 m34.5 m28.2 m44.9 m88.4 m34.1 m37.7 m39.2 m52.9 m12.8 m4 m3.9 m5.9 m

Operating expense total

34.2 m41.3 m35.2 m52.9 m97 m43.5 m47.5 m50 m68.6 m19.9 m10.5 m10.1 m9.5 m

EBIT

(34.2 m)(41.3 m)(35.2 m)107.7 m(92.6 m)(38.6 m)43.3 m(40.8 m)53 m(19.9 m)(10.5 m)(10.1 m)(9.5 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

68.1 m307.4 m188.2 m74.1 m34.6 m

Accounts Receivable

Inventories

11.1 m11.2 m9.5 m8.4 m

Current Assets

224.9 m344.6 m254.7 m101.7 m58.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

53.5 m55 m85.5 m321.3 m223 m134.6 m137.3 m113.8 m122.4 m98.5 m75.4 m66.2 m30.6 m

Current Assets

255 m194.3 m160.2 m390.7 m239.4 m208.5 m300.3 m208 m157.5 m123.5 m80.3 m68.8 m49.1 m

PP&E

4.1 m3.7 m3.4 m3 m22.7 m27.4 m28.1 m27.9 m25.7 m24.5 m22.7 m22 m156 k

Total Assets

260.8 m199.8 m165.6 m396.8 m267.6 m240.9 m333.2 m240.5 m187.3 m151.9 m103.6 m90.8 m50 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(126.8 m)(17.4 m)(128.4 m)(30.1 m)(41.8 m)

Depreciation and Amortization

1.8 m1.8 m2.3 m3.4 m1.7 m

Inventories

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(33.9 m)(42.3 m)(38 m)103.2 m(93.3 m)(38.4 m)42.5 m(40.7 m)53 m(19.5 m)(10.5 m)(9.5 m)

Depreciation and Amortization

63 k

Accounts Payable

3.9 m11 m5.7 m7.8 m11.2 m9.1 m12.7 m4.8 m733 k

Cash From Operating Activities

(9.3 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Infinity Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Infinity Pharmaceuticals News and Updates

Report incorrect company information